The Duke Clinical Research Institute, or DCRI, will lead a new clinical study to optimize care for people with type 2 diabetes and cardiovascular disease through evaluation of a multidisciplinary approach at cardiology clinics across the U.S. The research program, COORDINATE-Diabetes, will be funded by Boehringer Ingelheim and Eli Lilly. People with diabetes are up to four times more likely to develop cardiovascular disease than those without diabetes and cardiovascular disease ranks as their leading cause of death and disability despite available treatments. To help improve these statistics, COORDINATE-Diabetes will examine the impact of multifaceted interventions involving guideline-based therapies among cardiologists, endocrinologists, primary care providers and patients, including the recommendations outlined in the American Diabetes Association, or ADA, Standards of Medical Care in Diabetes and the American College of Cardiology, or ACC, Expert Consensus Decision Pathway on novel therapies for cardiovascular risk reduction in adults with type 2 diabetes and atherosclerotic cardiovascular disease. The trial will include 46 cardiology clinics in the U.S. and aims to enroll 30 patients at each site. The clinics will be randomized to a basic education arm or an intensive intervention arm. The care teams at the intervention sites will be encouraged to communicate with patients’ primary care physicians to facilitate a well-rounded, multidisciplinary approach to patient care. The trial will measure the impact of the intervention on the sites’ use of guideline-recommended therapies after 12 months. The trial will also leverage the power of electronic health record data from a consortium of health systems across the U.S. that have curated their data to support research and improve outcomes. Researchers will begin enrolling clinics and patients for the study in 2019 with the goal of sharing the main results by 2021.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.